Johnson & Johnson Subsidiary Fined $1.64 Billion Over Misleading HIV Drug Promotions
Philadelphia, PA – A U.S. jury has ruled against a Johnson & Johnson subsidiary, ordering the pharmaceutical giant to pay $1.64 billion in a landmark case that accuses the company of misleading marketing practices related to its HIV treatments. This verdict marks one of the largest in a series of legal challenges faced by the company. The case revolved around the allegations that Janssen Pharmaceuticals, a unit of Johnson & Johnson, engaged in false and misleading promotion of its drugs used to treat HIV. The lawsuit claimed that the company failed to adequately warn patients … Read more